Myostatin is a well-studied protein that limits muscle growth, and animals and rare human cases with myostatin mutations really do show dramatically increased muscle mass — which is the genuine science that gets cited to sell Follistatin-344, a protein that inhibits myostatin, as a research compound.
Real Biology, Different Molecule
The myostatin-knockout research is legitimate and well-replicated. But Follistatin-344 as sold in research-compound listings is a specific recombinant protein variant, and the human data on that specific product — dosing, systemic effects, safety — is essentially nonexistent.
“The myostatin story is real. The specific product being sold to act on it has essentially no human data of its own.”
— a muscle physiology researcher who reviewed the compound’s literature for this pieceWhy Systemic Follistatin Raises Its Own Questions
Follistatin inhibits more than just myostatin — it also affects other proteins in the same family involved in reproductive hormone regulation and other processes. Preclinical research has flagged potential systemic effects that go well beyond muscle.
What’s Missing
There’s no published human safety or efficacy data on injectable Follistatin-344 at the doses circulating in this market. The underlying muscle biology is sound; the specific product’s evidence base is not.